1 |
Huang R, Wu Y, Zou Z. Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects. Epigenomics 2023. [PMID: 36601794 DOI: 10.2217/epi-2022-0320] [Reference Citation Analysis]
|
2 |
Zhang L, Zhao F, Li W, Song G, Kasim V, Wu S. The Biological Roles and Molecular Mechanisms of Long Non-Coding RNA MEG3 in the Hallmarks of Cancer. Cancers (Basel) 2022;14. [PMID: 36551518 DOI: 10.3390/cancers14246032] [Reference Citation Analysis]
|
3 |
Hayakawa S, Ohishi T, Oishi Y, Isemura M, Miyoshi N. Contribution of Non-Coding RNAs to Anticancer Effects of Dietary Polyphenols: Chlorogenic Acid, Curcumin, Epigallocatechin-3-Gallate, Genistein, Quercetin and Resveratrol. Antioxidants (Basel) 2022;11. [PMID: 36552560 DOI: 10.3390/antiox11122352] [Reference Citation Analysis]
|
4 |
Ye M, Chen T, Hu C, Bai J, Zhong Y, Yan L, Kan J, Chen J, Lu F, Li X, Tian Y, Tang Q. Downregulation of FABP5 suppresses mTOR -mediated autophagy via an increase in FASN to promote colorectal cancer progression.. [DOI: 10.21203/rs.3.rs-1961306/v1] [Reference Citation Analysis]
|
5 |
Li M, Jiang H, Chen S, Ma Y. GATA binding protein 1 recruits histone deacetylase 2 to the promoter region of nuclear receptor binding protein 2 to affect the tumor microenvironment and malignancy of thyroid carcinoma. Bioengineered 2022;13:11320-41. [PMID: 35491849 DOI: 10.1080/21655979.2022.2068921] [Reference Citation Analysis]
|